Kayoko Hishinuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kayoko Hishinuma has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Atsuko Murashima
Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development Tokyo Japan
2 shared publicationsIkuko Yokoo
Department of Obstetrics and Gynecology Toranomon Hospital Minato‐ku Tokyo Japan
1 shared publicationItsuko Ishii
Division of Pharmacy Chiba University Hospital Chiba Japan
1 shared publicationKaori Yamazaki
Division of Pharmacy Chiba University Hospital Chiba Japan
1 shared publicationKen Nakajima
Department of Pharmacy Yokohama Minami Kyousai Hospital Yokohama Kanagawa Japan
1 shared publicationKunihiko Takahashi
Department of Biostatistics, M&D Data Science Center Tokyo Medical and Dental University Bunkyo‐ku Tokyo Japan
1 shared publication
Latest Publications
- 1 January 2026
- Published by Wiley in Congenital Anomalies
- Vol. 66 (1) , e70056
Cohort Study of Pregnancy Outcomes After Exposure to Fexofenadine or Olopatadine in the First Trimester
Medication safety must be carefully considered during pregnancy because of the potential risks to the fetus. Allergic diseases during pregnancy, oral second‐generation antihistamines, such as fexofenadine and olopatadine, are often used when topical agents are insufficiently effective. However, there are limited data on their teratogenic risk, particularly in the Japanese population. A cohort study was conducted using data from Japanese teratogenicity information services at two institutions: Toranomon Hospital and the National Center for Child Health and Development. Outcomes in pregnant women exposed to fexofenadine or olopatadine during the first trimester were compared with those in controls exposed to nonteratogenic drugs. The primary endpoint was the incidence of major birth defects defined by the EUROCAT criteria. Secondary outcomes included preterm birth and low birth weight. Logistic regression analyses were performed with adjustment for maternal age, alcohol consumption, smoking, and comorbidities. In total, 1473 eligible pregnancies for the analysis of major birth defects were included. Major birth defects occurred in 1.8% of the fexofenadine group ( n = 231) and 3.0% of the olopatadine group ( n = 186), showing no significant increase compared with 1.8% of the control group ( n = 1056). Logistic regression showed no association between either antihistamine and major birth defects, preterm birth, or low birth weight after adjustment. No consistent pattern of anomalies was identified. This study found no evidence that exposure to fexofenadine or olopatadine in the first trimester increases the risk of major birth defects. These second‐generation antihistamines appear to be relatively safe in pregnant women with allergic conditions.
- 1 January 2026
- Published by Wiley in Congenital Anomalies
- Vol. 66 (1) , e70056
Cohort Study of Pregnancy Outcomes After Exposure to Fexofenadine or Olopatadine in the First Trimester
Medication safety must be carefully considered during pregnancy because of the potential risks to the fetus. Allergic diseases during pregnancy, oral second‐generation antihistamines, such as fexofenadine and olopatadine, are often used when topical agents are insufficiently effective. However, there are limited data on their teratogenic risk, particularly in the Japanese population. A cohort study was conducted using data from Japanese teratogenicity information services at two institutions: Toranomon Hospital and the National Center for Child Health and Development. Outcomes in pregnant women exposed to fexofenadine or olopatadine during the first trimester were compared with those in controls exposed to nonteratogenic drugs. The primary endpoint was the incidence of major birth defects defined by the EUROCAT criteria. Secondary outcomes included preterm birth and low birth weight. Logistic regression analyses were performed with adjustment for maternal age, alcohol consumption, smoking, and comorbidities. In total, 1473 eligible pregnancies for the analysis of major birth defects were included. Major birth defects occurred in 1.8% of the fexofenadine group ( n = 231) and 3.0% of the olopatadine group ( n = 186), showing no significant increase compared with 1.8% of the control group ( n = 1056). Logistic regression showed no association between either antihistamine and major birth defects, preterm birth, or low birth weight after adjustment. No consistent pattern of anomalies was identified. This study found no evidence that exposure to fexofenadine or olopatadine in the first trimester increases the risk of major birth defects. These second‐generation antihistamines appear to be relatively safe in pregnant women with allergic conditions.
- Open Access
- 25 February 2021
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 47 (5) , 1704-1710
Pregnancy outcome after first trimester exposure to domperidone—An observational cohort study
Aim: To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.Methods: Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The incidence of major malformation was calculated among infants born to women taking domperidone (n = 519), nonteratogenic drugs (control, n = 1673), or metoclopramide (reference, n = 241) during the first trimester of pregnancy. Using the control group as reference, the crude odds ratio (OR) of the incidence of major malformation in the domperidone and metoclopramide groups was calculated using univariable logistic regression analysis. Adjusted OR was also calculated using multivariable logistic regression analysis adjusted for various other factors.Results: The incidence of major malformation was 2.9% (14/485, 95% confidence interval [CI]: 1.6–4.8) in the domperidone group, 1.7% (27/1554, 95%CI: 1.1–2.5) in the control group, and 3.6% (8/224, 95%CI: 1.6–6.9) in the metoclopramide group. The adjusted multivariable logistic regression analysis showed no significant difference in incidence between the control and domperidone groups (adjusted OR: 1.86 [95%CI: 0.73–4.70], p = 0.191) or between the control and metoclopramide groups (adjusted OR: 2.20 [95%CI: 0.69–6.98], p = 0.183).Conclusions: This observational cohort study showed that domperidone exposure during the first trimester was not associated with increased risk of major malformation in infants. These results may help alleviate the anxiety of patients who took domperidone during pregnancy.
- 25 February 2021
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 47 (5) , 1704-1710
Open AccessPregnancy outcome after first trimester exposure to domperidone—An observational cohort study
Aim: To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.Methods: Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The incidence of major malformation was calculated among infants born to women taking domperidone (n = 519), nonteratogenic drugs (control, n = 1673), or metoclopramide (reference, n = 241) during the first trimester of pregnancy. Using the control group as reference, the crude odds ratio (OR) of the incidence of major malformation in the domperidone and metoclopramide groups was calculated using univariable logistic regression analysis. Adjusted OR was also calculated using multivariable logistic regression analysis adjusted for various other factors.Results: The incidence of major malformation was 2.9% (14/485, 95% confidence interval [CI]: 1.6–4.8) in the domperidone group, 1.7% (27/1554, 95%CI: 1.1–2.5) in the control group, and 3.6% (8/224, 95%CI: 1.6–6.9) in the metoclopramide group. The adjusted multivariable logistic regression analysis showed no significant difference in incidence between the control and domperidone groups (adjusted OR: 1.86 [95%CI: 0.73–4.70], p = 0.191) or between the control and metoclopramide groups (adjusted OR: 2.20 [95%CI: 0.69–6.98], p = 0.183).Conclusions: This observational cohort study showed that domperidone exposure during the first trimester was not associated with increased risk of major malformation in infants. These results may help alleviate the anxiety of patients who took domperidone during pregnancy.